anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
[Problem] To develop an agent that satisfies the treatment of neuropathic pain. Namely, to develop an excellent neuropathic pain reducing agent for mammals, which has few side effects. [Solution] A neuropathic pain reducing agent for mammals or an antidepressant agent for mammals, which is characterized by containing a peptide represented by the following formula (1) as an active ingredient. x-y-Gly-Trp-NH2 (1) (In the formula, x and y each represents zero or one amino acid selected from among Pro, Gly, Ala, Val, Leu, Ile, Met, Phe and Trp.) Consequently, a low-cost neuropathic pain reducing agent for mammals having few side effects is able to be provided. Since these peptides increase the amount of brain serotonin, these peptides can be provided as antidepressant agents for mammals.
A system and method for extracting relevant data elements from a file for conversion to a tabular format includes a computing device receiving an XML format file having a loop with nested blocks. Each of the blocks has at least one data element. Features are extracted from each data element. These extracted features are processed using a machine learning algorithm to estimate a column header value for the data elements relative to a data schema. With the data element classified, a configuration file is generated to map the column header value to the data elements of the XML file. The configuration file is used to extract the data elements from the XML file to a tabular format. In the healthcare industry, the system and method may be used to extract relevant health information from a clinical document for conversion to a tabular format.
Methods, apparatus, media, and a data model for managing prescription records. A prescription request is received from a prescriber, the prescription request including prescription data describing a prescription and, optionally, a value in cryptographic tokens associated with the prescription data. The request is approved if the prescriber is an authorized prescriber. Prescription data is recorded as a prescription record. A cryptographic hash of at least some of the prescription data and auxiliary information is created as a unique identifier for the prescription and the hash, a prescriber ID, a pharmacy ID and a patient ID are recorded on a blockchain as an issue transaction corresponding to the prescription. An acceptance message is received indicating that a pharmacy is willing to fill the prescription. If the acceptance message is verified, an accept transaction is recorded on a blockchain corresponding to the prescription, the accept transaction including the hash.
Thirty-one (31) participants with DEB, aged 6 months or older at time of consent were enrolled for this Phase III study. The trial duration for each subject was about 6 months, with administration occurring once weekly. A Safety Follow-up Visit occurring 30 days from the date of final treatment with the Investigational Product also occurred. Each subject provided one pair of primary target wounds, with one wound from each pair randomized to be treated with B-VEC and the other wound with placebo. In addition to the primary target wound pair(s), additional wounds (secondary wounds) were selected to be treated with B-VEC. Throughout the study, participants complete questionnaires, had images captured of their study wounds, underwent physical exams, had vital signs and safety labs monitored.
Patients undergo bone marrow biopsy using the power drill. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.
The subject of the present invention relates to the new strain Bifidobacterium longum ssp. longum 3/15, filed under No. NBIMCC 9085 with the National Bank for Industrial Microorganisms and Cell Cultures (NBIMCC) of the Republic of Bulgaria, possessing a complex of health beneficial properties: hypolipidemic activity, anti-inflammatory immunomodulatory activity, ability to reduce insulin resistance, strong adhesion to epithelial cells and high survival rate in the gastrointestinal tract. The subject of the present invention is also a bifidobacterial preparation obtained by cultivating the strain Bifidobacterium longum ssp. longum 3/15 NBIMCC 9085 with a clinically proven set of functional effects, including improvement of lipid indicators, reduction of insulin resistance, beneficial effect on markers of inflammatory status. The invention also relates to the use of the new strain Bifidobacterium longum ssp. longum 3/15 NBIMCC 9085 and the bifidobacterial preparation for the prevention and therapy of atherosclerosis, cardiovascular and inflammatory diseases and to reduce the diabetes risk.
Participants in the control group receive usual care alone. Additional ePROMs will be completed at baseline, 4, 8, 12 and 20 weeks.
The volunteers performed in random order two experimental sessions separated by 48 hours and being: 1) Control and; 2) Inhalation Essential Oil of Eucalyptus. The experimental sessions were always performed in the morning and in the same time of day for the same volunteer, avoiding possible influences circadian rhythm. The experimental sessions were held at the Exercise Physiology Laboratory at the Federal University of Vale do São Francisco with controlled temperature 25°C. At times the pre session (rest), recovery and during the isometric resistance exercise (post-session) in upper limb by hand grip, blood pressure measurements were taken, heart rate and records of the intervals R-R in the absolute time and frequency domain, and are calculated the rate product pressure values (systolic blood pressure x heart rate). Using a disposable face mask participants inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus. In the control session the volunteers remained in a similar manner, with the installed face mask, however inhaling fresh air. The test for determining the maximal voluntary contraction was held in hand grip device Hydraulic Hand Dynamometer Saehan Model SH5001 ranging from 0-90 kgf of grip and precision of 2 kgf. Before the test was performed familiarization session with two series each of 10 seconds with the minimum load allowed by the equipment, the series being separated by a 2-minute recovery period. The value of the maximum voluntary load was determined by the highest value obtained in three attempts of 10 seconds each, with 2 minutes between each trial and the position of the grip handle has been self selected. The experimental isometric resistance exercise sessions were undertaken after 48 hours of interval maximum voluntary contraction test, and the same equipment previously used for the test. The isometric resistance exercise series were held with volunteers sitting positioned comfortably and with the shoulder adducted, the elbow flexed at 90° and the forearm in neutral position, and the position of the self selected grip handle. The highest value obtained in kgf in maximum voluntary contraction test was used as a reference to calculate the absolute intensity of the exercise, which was corresponding to the relative intensity of 30% of the test. Three sets were performed with duration of 1 minute recovery at the same time in both sessions (Eucalyptus Essential Oil and Control).
The invention discloses a medicament for treating osteoarthritis and application thereof. Belongs to the field of medicine, and the medicine contains baicalein which exists in the form of small molecular compound. The medicine comprises baicalein and pharmaceutically acceptable pharmaceutical excipients which are mixed to form powder, paste, powder, injection, aqueous solution, enteric sustained release preparation or injection. Baicalein can reduce cartilage loss by inhibiting chondrocyte apoptosis, and can inhibit joint synovitis so as to delay the progress of osteoarthritis. The invention provides a new medicament for the clinical treatment of osteoarthritis and simultaneously explains the mechanism of the novel medicament. Provides a new idea and reference for better understanding of the pathological process of osteoarthritis and the development of the osteoarthritis treatment drugs in the future.
AIMS: Follicular helper T-cell (TFH) lymphoma of the angioimmunoblastic-type (AITL), one of the most prevalent T-cell lymphomas, typically encompasses proliferation of high endothelial venules and Epstein-Barr virus-positive immunoblasts, but neither infection with HHV8 nor association with Kaposi's sarcoma (KS) have been described. The aims of this study are to characterise the association between AITL and HHV8 infection or KS.
METHODS AND RESULTS: Three male patients aged 49-76 years, HIV-negative, with concurrent nodal involvement by AITL and KS, were identified from our files and carefully studied. Two patients originated from countries where endemic KS occurs, including one with cutaneous KS. The lymphomas featured abundant vessels, expanded follicular dendritic cells and neoplastic TFH cells [PD1+ (three of three), ICOS+ (three of three), CXCL13+ (three of three), CD10+ (two of three), BCL6 (two of three)] but lacked EBV+ immunoblasts. The foci of KS consisted of subcapsular proliferations of ERG+, CD31+ and/or CD34+ , HHV8+ spindle cells. High-throughput sequencing showed AITL-associated mutations in TET2 (three of three), RHOA (G17V) (three of three) and IDH2 (R172) (two of three), which were absent in the microdissected KS component in two cases. Relapses in two patients consisted of AITL, without evidence of KS. No evidence of HHV8 infection was found in a control group of 23 AITL cases.
CONCLUSION: Concurrent nodal involvement by AITL and KS is rare and identification of both neoplastic components may pose diagnostic challenges. The question of whether the association between AITL and KS may be fortuitous or could reflect the underlying immune dysfunction in AITL remains open.
Previous research has demonstrated high rates of depression in people with pulmonary hypertension (PH). The psychological interventions that support people with depression are not made specific to people with PH and may not be relevant for them, and there is limited evidence examining psychological treatments for depression in people with PH. The aim of this study is to develop and test a self-help psychological intervention for depression based on cognitive behavioural therapy (CBT), which has been developed specifically for individuals with PH. When participants have agreed to take part, they will be allocated at random into an intervention or wait-list group. The self-help materials will be provided online (for people outside of the UK) or posted in paper form (for those living in the UK) and will take four weeks to complete at home. Both groups will complete questionnaires at the same time points (before starting the study, after four weeks and after eight weeks (pre-, post-intervention and one-month follow up). In addition, the intervention group will be contacted after two weeks of their participation and asked about their experiences of the intervention and participation in the study - measuring acceptability of the intervention. The intervention group will also be asked to complete a feedback questionnaire after completing the intervention to further examine acceptability. Analysis will be conducted by the researcher to examine whether the self-help intervention reduced depression in individuals with PH, compared to those with PH who did not receive the intervention. The potential benefit of the study includes a new intervention for depression in people with PH. When the study is completed, if the intervention is found to be helpful and safe, then the people who took part in the study and did not receive the intervention will be offered the intervention.
Advise the patient to read the FDA-approved patient labeling (Patient Information).

Pregnancy: Advise female patients of childbearing age about the consequences of exposure to telmisartan and amlodipine tablets during pregnancy. Discuss treatment options with women planning to become pregnant. Tell patients to report pregnancies to their physicians as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)].

Lactation: Advise nursing women not to breastfeed during treatment with telmisartan and amlodipine tablets [see Use in Specific Populations (8.2)].

Symptomatic Hypotension: Advise patients that lightheadedness can occur, especially during the first days of therapy, and to report it to their healthcare provider. Inform patients the inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope. Advise patients to contact their healthcare provider if syncope occurs [see Warnings and Precautions (5.2)].
This tutorial discusses a methodology for causal inference using longitudinal modified treatment policies. This method facilitates the mathematical formalization, identification, and estimation of many novel parameters and mathematically generalizes many commonly used parameters, such as the average treatment effect. Longitudinal modified treatment policies apply to a wide variety of exposures, including binary, multivariate, and continuous, and can accommodate time-varying treatments and confounders, competing risks, loss to follow-up, as well as survival, binary, or continuous outcomes. Longitudinal modified treatment policies can be seen as an extension of static and dynamic interventions to involve the natural value of treatment and, like dynamic interventions, can be used to define alternative estimands with a positivity assumption that is more likely to be satisfied than estimands corresponding to static interventions. This tutorial aims to illustrate several practical uses of the longitudinal modified treatment policy methodology, including describing different estimation strategies and their corresponding advantages and disadvantages. We provide numerous examples of types of research questions that can be answered using longitudinal modified treatment policies. We go into more depth with one of these examples, specifically, estimating the effect of delaying intubation on critically ill COVID-19 patients' mortality. We demonstrate the use of the open-source R package lmtp to estimate the effects, and we provide code on https://github.com/kathoffman/lmtp-tutorial.
PROBLEM TO BE SOLVED: To make kidney dialysis safely so as to be carried out even in another hospital by storing records of kidney dialysis of individual patients and inspection data and inspection images on electronic recording media. SOLUTION: Inspection data such as dialysis records, kidney dialysis system 1, fundus images taken by a fundus camera 11, shunts taken by a digital camera 12, chest X-ray images, etc. of each patient in the past are stored on an electronic memory medium 2 of this kidney dialysis system. Those records and data are stored sorted by identification keys including patient ID, kind of image, date, and sequential number. When a doctor in charge inputs the identification key into a reference terminal 4, the kidney dialysis system 1 displays the required patient's data from the inputted data on the reference terminal 4. Correct dialysis is carried out by setting the dialysis condition by the displayed data. It is also preferable to add a function to acknowledge a user for secret keeping or internet connection.
Segmental neural therapy will be administered with intradermal 0.5% lidocaine from cervical 1st to sacral 1st vertebra and upper trapezius region with quaddel injections.. Sham kinesio taping will be applied to the bilateral arms of the patients. Home exercise program; trapezius stretching, cervical, thoracic and lumbar paravertebral muscle stretching exercises will be required to be performed 10 times and every day.
NEW MATERIAL:A compound expressed by formula I [R<1> is (substituted) aryl; R<2> is halogen] and a salt thereof. EXAMPLE:5-Chloro-6-phenoxy-2-benzoxazolone. USE:An anti-inflammatory agent or antithrombotic agent, which may be administered in 1-6,000mg/individual or more dose per day. PREPARATION:A compound expressed by the formula R<1>-OH is reacted with a compound expressed by formula IV (R<3> is lower alkyl; R<2> is acid residue) to give a compound, which is then delakylated and reduced to afford a novel compound expressed by formula II or a salt thereof. The resultant compound expressed by formula II or salt thereof is then reacted with a compound expressed by formula III (Z and Z' are eliminative group) in a solvent, e.g. ethyl acetate, in the presence of a base, e.g. sodium acetate, under cooling, at ordinary temperature, under warming or heating to give the aimed compound expressed by formula I .
A two sided digital platform for medical patients and medical providers is described in this document. On the provider side, users are able to create digital healthcare assets and programs which prescribe a set of instructions to patients. These instructions may vary from a detailed long-term medical care-plan to a quick survey of questions to be filled. From the patient side, users may browse medical programs which are made open by providers, as well as be assigned personalized programs by their caregivers. Feedback is given to the system by both providers and patients, which feeds a recommendation mechanism that suggests patients relevant programs that may help them achieve healthcare and lifestyle goals. Users are able to view their programs in a compartmentalized view, whether it is providers editing their programs under both public and private settings or patients reviewing all of the programs they are enrolled in and assigned divided based on the programs' inherent instructions. Patients' adherence to programs is constantly reviewed, and intelligent notifications and motivations are presented to patients to ensure constant improvement and optimal progress.
The most important function of sleep is to restore physical energy lost after activities during the day, and to adjust and reorganize people's emotions, behavior, and cognitive memory. The average adult sleeps about 7 to 8 hours. Good sleep quality has a great impact on the performance of work and study during the day. If a person does not get enough sleep for a long time, it is easy to suffer from memory loss, emotional instability and other phenomena. It will also affect the operation of the immune system and easily lead to colds and illnesses. The following statements are often complained by sleep disorder patient: 1. Difficulty falling asleep. 2. Difficulty maintaining sleep, often waking up suddenly in the middle of sleep or having difficulty falling back to sleep once woken up. 3. Waking up too early and having trouble falling back to sleep. This study aims to evaluate the feasibility of probiotics in improving sleep indicators through clinical human studies. Previous animal experiments have confirmed that Limosilactob acillus fermentum PS150 and heat-treated Lactobacillus fermentum HT-PS150 strains have the effect of improving sleep.
The sulfate salts of sodium, potassium, and magnesium contained in Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution were administered orally (gavage) to rats and dogs up to 28 days up to a maximum daily dose of 5 grams/kg/day (approximately 0.9 and 3 times for rats and dogs, respectively, the recommended human dose of 44 grams/day or 0.89 grams/kg based on the body surface area). In rats, the sulfate salts caused diarrhea and electrolyte and metabolic changes, including hypochloremia, hypokalemia, hyponatremia, lower serum osmolality, and high serum bicarbonate. Significant renal changes included increased fractional sodium excretion, increased urinary sodium and potassium excretion, and alkaline urine in both males and females. In addition, creatinine clearance was significantly decreased in females at the highest dose. No microscopic renal changes were seen. In dogs, the sulfate salts caused emesis, excessive salivation, excessive drinking of water, and abnormal excreta (soft and/or mucoid feces and/or diarrhea) and increased urine pH and sodium excretion.
BACKGROUND/OBJECTIVES: Aneuploidy is a prevalent cancer feature that occurs in many solid tumors. For example, high-grade serous ovarian cancer shows a high level of copy number alterations and genomic rearrangements. This makes genomic variants appealing as diagnostic or prognostic biomarkers, as well as for their easy detection. In this study, we focused on copy number (CN) losses shared by ovarian cancer stem cells (CSCs) to identify chromosomal regions that may be important for CSC features and, in turn, for patients' prognosis.
METHODS: Array-CGH and bioinformatic analyses on three CSCs subpopulations were performed.
RESULTS: Pathway and gene ontology analyses on genes involved in copy number loss in all CSCs revealed a significant decrease in mRNA surveillance pathway, as well as miRNA-mediated gene silencing. Then, starting from these CN losses, we validated their potential prognostic relevance by analyzing the TCGA cohort. Notably, losses of 4q34.3-q35.2, 8p21.2-p21.1, and 18q12.2-q23 were linked to increased genomic instability. Loss of 18q12.2-q23 was also related to a higher tumor stage and poor prognosis. Finally, specific genes mapping in these regions, such as PPP2R2A and TPGS2A, emerged as potential biomarkers.
CONCLUSIONS: Our findings highlight the importance of genomic alterations in ovarian cancer and their impact on tumor progression and patients' prognosis, offering advance in understanding of the application of numerical aberrations as prognostic ovarian cancer biomarkers.
The relative importance of dietary patterns vs. macronutrient composition in affecting energy intake and body weight remains uncertain. In this study we propose to investigate the relative effects of dietary variety vs dietary fat on voluntary energy intake in adults. We will quantify and compare the effects of typical ranges of variety \& fat intakes in the American diet on voluntary energy intake. The primary hypotheses to be tested are 1)an increasing availability of entree/side/snack/dessert variety offered will significantly increase voluntary energy intake in a dose-response fashion when other dietary factors known to influence energy intake are held constant. 2)The separate effects of dietary variety \& dietary fat on energy intake will be similar.

We anticipate that the results of this investigation will lead to a greater understanding of the relative importance of eating patterns versus macronutrient composition in the etiology of obesity, and more specifically, dietary variety versus dietary fat in determining energy intake. More importantly, it will help lay a foundation for improved dietary recommendations concerning weight loss and prevention of excess weight gain in adulthood
This is an observational, prospective, multi-center study to obtain information about the symptoms and treatment received for patients with behavioral and psychological symptoms of dementia (BPSD). Patients must first meet eligibility criteria and sign informed consent. Patient treatment will be based upon investigator opinion. The following parameters will be assessed: patient's characteristics, Clinical Global Impression (CGI) score, Neuropsychiatric Inventory (NPI), and Minimal Mental Status Examination (MMSE). Each patient will be observed for 12 weeks. Medication dosing regimen will be flexible throughout the study and is based on patient response and investigator judgment. During the study observation period, all patients will attend clinic visits for the subsequent 12 weeks (visit 2 to 3) as is the usual clinical practice. Patients can visit clinics on additional dates as needed or by request. At the pre-planned clinic visits, CGI score, NPI, vital signs, reports of adverse events, drug information, and MMSE score (visit 3) will be recorded. This is an observational study and no study drug is administered.